- Home
- NIVF vs HOTH Comparison
NIVF vs HOTH Comparison
Compare NIVF & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- HOTH
- Stock Information
- Founded
- NIVF 2011
- HOTH 2017
- Country
- NIVF Hong Kong
- HOTH United States
- Employees
- NIVF N/A
- HOTH N/A
- Industry
- NIVF
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- HOTH Health Care
- Exchange
- NIVF NYSE
- HOTH Nasdaq
- Market Cap
- NIVF 5.2M
- HOTH 5.8M
- IPO Year
- NIVF N/A
- HOTH 2019
- Fundamental
- Price
- NIVF $0.35
- HOTH $0.82
- Analyst Decision
- NIVF
- HOTH Strong Buy
- Analyst Count
- NIVF 0
- HOTH 4
- Target Price
- NIVF N/A
- HOTH $4.75
- AVG Volume (30 Days)
- NIVF 6.4M
- HOTH 155.3K
- Earning Date
- NIVF 02-16-2025
- HOTH 12-31-2024
- Dividend Yield
- NIVF N/A
- HOTH N/A
- EPS Growth
- NIVF N/A
- HOTH N/A
- EPS
- NIVF N/A
- HOTH N/A
- Revenue
- NIVF $5,679,218.00
- HOTH N/A
- Revenue This Year
- NIVF N/A
- HOTH N/A
- Revenue Next Year
- NIVF N/A
- HOTH N/A
- P/E Ratio
- NIVF N/A
- HOTH N/A
- Revenue Growth
- NIVF N/A
- HOTH N/A
- 52 Week Low
- NIVF $0.24
- HOTH $0.58
- 52 Week High
- NIVF $17.24
- HOTH $1.73
- Technical
- Relative Strength Index (RSI)
- NIVF 44.71
- HOTH 47.10
- Support Level
- NIVF $0.30
- HOTH $0.73
- Resistance Level
- NIVF $0.43
- HOTH $0.85
- Average True Range (ATR)
- NIVF 0.08
- HOTH 0.04
- MACD
- NIVF 0.01
- HOTH -0.00
- Stochastic Oscillator
- NIVF 45.05
- HOTH 57.00
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.